Compounds > polymyxin b2
Page last updated: 2024-11-12

polymyxin b2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11982455
CHEMBL ID1088938
CHEBI ID59063
SCHEMBL ID534885
MeSH IDM0572919

Synonyms (12)

Synonym
4,10-anhydro[n-(6-methylheptanoyl)-l-2,4-diaminobutanoyl-l-threonyl-l-2,4-diaminobutanoyl-l-2,4-diaminobutanoyl-l-2,4-diaminobutanoyl-d-phenylalanyl-l-leucyl-l-2,4-diaminobutanoyl-l-2,4-diaminobutanoyl-l-threonine]
chebi:59063 ,
CHEMBL1088938
unii-99sjo09vh2
99sjo09vh2 ,
l-threonine, n2-(6-methyl-1-oxoheptyl)-l-2,4-diaminobutanoyl-l-threonyl-l-2,4-diaminobutanoyl-l-2,4-diaminobutanoyl-l-2,4-diaminobutanoyl-d-phenylalanyl-l-leucyl-l-2,4-diaminobutanoyl-l-2,4-diaminobutanoyl-, cyclic (10-4)-peptide
34503-87-2
n2-(6-methyl-1-oxoheptyl)-l-2,4-diaminobutanoyl-l-threonyl-l-2,4-diaminobutanoyl-l-2,4-diaminobutanoyl-l-2,4-diaminobutanoyl-d-phenylalanyl-l-leucyl-l-2,4-diaminobutanoyl-l-2,4-diaminobutanoyl-l-threonine (10->4)-lactam
SCHEMBL534885
n-((s)-4-amino-1-(((2s,3r)-1-(((s)-4-amino-1-oxo-1-(((3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-((r)-1-hydroxyethyl)-12-isobutyl-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl)amino)butan-2-yl)amino)-3-hydro
Q27126427
n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1r)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
polymyxinPolymyxins are antibiotics with a general structure consisting of a cyclic peptide with a long hydrophobic tail. They disrupt the structure of the bacterial cell membrane by interacting with its phospholipids. Polymyxins are produced by the Gram-positive bacterium Bacillus polymyxa and are selectively toxic for Gram-negative bacteria.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID1494282Antibacterial activity against Acinetobacter baumannii ATCC 19606 after 18 hrs by agar dilution method2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics.
AID1437936Elimination half life in Sprague-Dawley rat at 0.8 mg/kg, iv administered as single bolus dose by LC-MS/MS analysis
AID1494280Antibacterial activity against NDM-1 producing Klebsiella pneumoniae ATCC BAA-2146 after 18 hrs by agar dilution method2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics.
AID1494283Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics.
AID1767080Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of bacterial growth incubated for 24 hrs by broth microdilution method
AID1494281Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 18 hrs by agar dilution method2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics.
AID1494277Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs by agar dilution method2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics.
AID1437934Total clearance in Sprague-Dawley rat at 0.8 mg/kg, iv administered as single bolus dose by LC-MS/MS analysis
AID476049Antimicrobial activity against Pseudomonas aeruginosa2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Structure--activity relationships of polymyxin antibiotics.
AID476050Displacement of dansyl-PMB from LPS by isothermal titration calorimetry2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Structure--activity relationships of polymyxin antibiotics.
AID1437942Protein binding in rat plasma up to 10 ug/ml after 2 hrs by LC-MS/MS based equilibrium dialysis method
AID476048Antimicrobial activity against Salmonella enterica2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Structure--activity relationships of polymyxin antibiotics.
AID1494284Acute toxicity in iv dosed ICR mouse assessed as survival measured daily for 7 days2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics.
AID1494278Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 14-11 after 18 hrs by agar dilution method2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics.
AID1491114Antibacterial activity against Acinetobacter baumannii ATCC 19606 infected in mouse assessed as reduction in bacterial count in blood at 4 mg/kg, ip measured after 4 hrs2017Journal of natural products, 05-26, Volume: 80, Issue:5
Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of Paenibacillus polymyxa ATCC 10401.
AID1491113Antibacterial activity against Klebsiella pneumoniae isolate FADDI-KP032 infected in mouse assessed as reduction in bacterial count in blood at 4 mg/kg, ip measured after 4 hrs2017Journal of natural products, 05-26, Volume: 80, Issue:5
Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of Paenibacillus polymyxa ATCC 10401.
AID1437933Plasma concentration in Sprague-Dawley rat at 0.8 mg/kg, iv administered as single bolus dose after 360 mins by LC-MS/MS analysis
AID476047Antimicrobial activity against Escherichia coli2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Structure--activity relationships of polymyxin antibiotics.
AID1437938Drug recovery in Sprague-Dawley rat urine at 0.8 mg/kg, iv administered as single bolus dose by LC-MS/MS analysis
AID1494286Nephrotoxicity in ICR mouse assessed as induction of prominent nuclei at 2.5 mg/kg, iv bid for 7 days measured after 2 hrs post last dose by hematoxylin and eosin staining based assay2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics.
AID1491095Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 18 hrs by broth microdilution method2017Journal of natural products, 05-26, Volume: 80, Issue:5
Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of Paenibacillus polymyxa ATCC 10401.
AID1437940Clearance in Sprague-Dawley rat at 4 mg/kg, iv administered as single bolus cassette dose by UPLC-MS/MS analysis
AID1494279Antibacterial activity against extended-spectrum beta-lactamase producing Klebsiella pneumoniae 700603 after 18 hrs by agar dilution method2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics.
AID1491105Antibacterial activity against Klebsiella pneumoniae isolate FADDI-KP032 after 18 hrs by broth microdilution method2017Journal of natural products, 05-26, Volume: 80, Issue:5
Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of Paenibacillus polymyxa ATCC 10401.
AID1437935Volume of distribution in Sprague-Dawley rat at 0.8 mg/kg, iv administered as single bolus dose by LC-MS/MS analysis
AID1494285Nephrotoxicity in ICR mouse assessed as tubular dilation at 2.5 mg/kg, iv bid for 7 days measured after 2 hrs post last dose by hematoxylin and eosin staining based assay2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics.
AID1494287Nephrotoxicity in ICR mouse assessed as pale tubular casts at 2.5 mg/kg, iv bid for 7 days measured after 2 hrs post last dose by hematoxylin and eosin staining based assay2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics.
AID1437939Protein binding in Sprague-Dawley rat plasma at 5 mg/L after 30 mins by ultracentrifugation based LC-MS/MS method
AID1491100Antibacterial activity against Acinetobacter baumannii ATCC 19606 after 18 hrs by broth microdilution method2017Journal of natural products, 05-26, Volume: 80, Issue:5
Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of Paenibacillus polymyxa ATCC 10401.
AID1491115Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 infected in mouse assessed as reduction in bacterial count in blood at 4 mg/kg, ip measured after 4 hrs2017Journal of natural products, 05-26, Volume: 80, Issue:5
Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of Paenibacillus polymyxa ATCC 10401.
AID1437937AUC (0 to infinity) in Sprague-Dawley rat at 0.8 mg/kg, iv administered as single bolus dose by LC-MS/MS analysis
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.13 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
polymyxin b nonapeptide
[no description available]		3.1510
circulin b
[no description available]		2.1710
polymyxin b(1)
[no description available]		2.5720
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Infections, Gram-Negative
[description not available]		02.9710
Gram-Negative Bacterial Infections
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.		02.9710